AU2008224657B2 - Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases - Google Patents

Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases Download PDF

Info

Publication number
AU2008224657B2
AU2008224657B2 AU2008224657A AU2008224657A AU2008224657B2 AU 2008224657 B2 AU2008224657 B2 AU 2008224657B2 AU 2008224657 A AU2008224657 A AU 2008224657A AU 2008224657 A AU2008224657 A AU 2008224657A AU 2008224657 B2 AU2008224657 B2 AU 2008224657B2
Authority
AU
Australia
Prior art keywords
cancer
compound
phenyl
kinase
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008224657A
Other languages
English (en)
Other versions
AU2008224657A1 (en
Inventor
Martyn Frederickson
Kyla Merriom Grimshaw
David Charles Rees
Steven John Woodhead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital, Cancer Research Technology Ltd, Astex Therapeutics Ltd filed Critical Institute of Cancer Research Royal Cancer Hospital
Publication of AU2008224657A1 publication Critical patent/AU2008224657A1/en
Application granted granted Critical
Publication of AU2008224657B2 publication Critical patent/AU2008224657B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C07C215/32—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
    • C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2008224657A 2007-03-14 2008-03-14 Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases Ceased AU2008224657B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89475207P 2007-03-14 2007-03-14
GB0704932.3 2007-03-14
GBGB0704932.3A GB0704932D0 (en) 2007-03-14 2007-03-14 Pharmaceutical compounds
US60/894,752 2007-03-14
PCT/GB2008/050180 WO2008110846A2 (en) 2007-03-14 2008-03-14 Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases

Publications (2)

Publication Number Publication Date
AU2008224657A1 AU2008224657A1 (en) 2008-09-18
AU2008224657B2 true AU2008224657B2 (en) 2014-06-26

Family

ID=38008428

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008224657A Ceased AU2008224657B2 (en) 2007-03-14 2008-03-14 Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases

Country Status (23)

Country Link
US (2) US20100113551A1 (https=)
EP (2) EP2134339B1 (https=)
JP (2) JP2010521446A (https=)
KR (1) KR20100014720A (https=)
CN (1) CN101686965B (https=)
AU (1) AU2008224657B2 (https=)
BR (1) BRPI0808802A2 (https=)
CA (1) CA2679878A1 (https=)
CY (1) CY1115877T1 (https=)
DK (1) DK2134339T3 (https=)
ES (1) ES2511817T3 (https=)
GB (1) GB0704932D0 (https=)
HR (1) HRP20141034T1 (https=)
IL (1) IL200822A (https=)
MX (1) MX2009009874A (https=)
NZ (1) NZ579341A (https=)
PL (1) PL2134339T3 (https=)
PT (1) PT2134339E (https=)
RS (1) RS53580B1 (https=)
RU (1) RU2527151C2 (https=)
SI (1) SI2134339T1 (https=)
WO (1) WO2008110846A2 (https=)
ZA (1) ZA200906303B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418078A8 (pt) 2003-12-23 2018-01-02 Astex Therapeutics Ltd composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
JP5345842B2 (ja) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
CA3121743A1 (en) 2009-01-15 2010-07-22 Incyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
RU2657832C1 (ru) * 2017-06-07 2018-06-15 федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" Антидиабетическое средство
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
EP4125910B1 (en) * 2020-03-25 2025-11-12 Woolsey Pharmaceuticals, Inc. Rho kinase inhibitors for treating frontotemporal dementia
CN111707830B (zh) * 2020-07-16 2023-08-15 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断肺损害中的应用
WO2022125056A1 (en) 2020-12-07 2022-06-16 Kimberly-Clark Worldwide, Inc. Methods and consumer products for detecting a metabolite
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061463A1 (en) * 2003-12-23 2005-07-07 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
WO2006136830A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Aryl-alkylamines and heteroaryl-alkylamines as protein kinase inhibitors
WO2006136837A2 (en) * 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
WO2006136821A1 (en) * 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2046628A1 (en) 1989-02-08 1990-08-09 Dee W. Brooks 4-hydroxythiazoles as 5-lipoxygenase inhibitors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5049570A (en) 1990-01-23 1991-09-17 Du Pont Merck Pharmaceutical Company Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5532356A (en) 1995-06-06 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N,N'-disubstituted cyclic ureas
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
JP2000507593A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
GB2339298B (en) 1996-04-30 2000-05-10 Eastman Kodak Co Use of pyrazolone image dye-forming couplers for enhancing light stability
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
GB9700555D0 (en) 1997-01-13 1997-03-05 Merck Sharp & Dohme Therapeutic agents
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
AU759772B2 (en) 1998-01-29 2003-05-01 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds
WO2000007996A2 (en) 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
US6503905B1 (en) 1998-12-29 2003-01-07 Pfizer Inc 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
AU4308300A (en) 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
CA2372044A1 (en) 1999-05-14 2000-11-23 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
WO2002088090A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
DE60226154T2 (de) 2001-08-03 2009-05-20 Vertex Pharmaceuticals Inc., Cambridge Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
FR2830192B1 (fr) 2001-09-28 2004-08-20 Oreal Composition tinctoriale comprenant une base d'oxydation du type diaminopyrazole et un coupleur pyrazolo-azole
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
RS52392B (sr) 2002-02-14 2013-02-28 Pharmacia Corporation Supstituisani piridinoni kao modulatori p38 map kinaze
CA2479338A1 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
ES2575354T3 (es) 2002-04-08 2016-06-28 Boston Scientific Scimed, Inc. Dispositivos y procedimientos de saciedad
AU2003223708A1 (en) 2002-04-23 2003-11-10 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
ES2385378T3 (es) 2002-07-24 2012-07-24 Dermira (Canada), Inc. Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos
CA2498046A1 (en) 2002-09-18 2004-04-01 The Curators Of The University Of Missouri Opiate analogs selective for the delta-opioid receptor
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
CA2530389A1 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
US20050192314A1 (en) 2003-11-13 2005-09-01 Ambit Biosciences Corporation Urea derivatives as C-kit modulators
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
GB0329617D0 (en) * 2003-12-23 2004-01-28 Astex Technology Ltd Pharmaceutical compounds
RU2419612C2 (ru) * 2003-12-23 2011-05-27 Астекс Терапьютикс Лимитед Производные пиразола в качестве модуляторов протеинкиназы
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
GB2427406A (en) 2005-06-21 2006-12-27 Astex Technology Ltd Silicon-containing PKB/PKA kinase inhibitors
JP2008543919A (ja) 2005-06-21 2008-12-04 アステックス・セラピューティクス・リミテッド 医薬化合物
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061463A1 (en) * 2003-12-23 2005-07-07 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
WO2006136830A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Aryl-alkylamines and heteroaryl-alkylamines as protein kinase inhibitors
WO2006136821A1 (en) * 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) * 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators

Also Published As

Publication number Publication date
KR20100014720A (ko) 2010-02-10
SI2134339T1 (sl) 2014-12-31
PL2134339T3 (pl) 2015-04-30
CN101686965A (zh) 2010-03-31
NZ579341A (en) 2012-08-31
JP2010521446A (ja) 2010-06-24
US20110269808A1 (en) 2011-11-03
IL200822A (en) 2016-09-29
WO2008110846A2 (en) 2008-09-18
DK2134339T3 (da) 2014-11-03
RU2009137779A (ru) 2011-05-10
HRP20141034T1 (hr) 2014-12-19
US20100113551A1 (en) 2010-05-06
RS53580B1 (sr) 2015-02-27
PT2134339E (pt) 2014-11-03
JP2015028033A (ja) 2015-02-12
BRPI0808802A2 (pt) 2017-05-02
ES2511817T3 (es) 2014-10-23
GB0704932D0 (en) 2007-04-25
US8497294B2 (en) 2013-07-30
EP2433632A1 (en) 2012-03-28
CN101686965B (zh) 2014-09-17
RU2527151C2 (ru) 2014-08-27
HK1133828A1 (en) 2010-04-09
CA2679878A1 (en) 2008-09-18
AU2008224657A1 (en) 2008-09-18
WO2008110846A3 (en) 2009-03-05
IL200822A0 (en) 2010-05-17
EP2134339B1 (en) 2014-09-17
ZA200906303B (en) 2015-08-26
EP2134339A2 (en) 2009-12-23
MX2009009874A (es) 2009-09-24
CY1115877T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
AU2008224657B2 (en) Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
CN113365994B (zh) 哒嗪基噻唑甲酰胺类化合物
EP3719018B1 (en) Purine and deazapurine derivatives as pharmaceutical compounds
CN106188138B (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
US20090253718A1 (en) Pharmaceutical Compounds
CN104736155B (zh) 双环化合物作为激酶的抑制剂
US20100016340A1 (en) Pharmaceutical compounds
PT1945631E (pt) Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
JP2008540391A (ja) ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
HK1133828B (en) Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
CN107721937A (zh) 含有嘧啶酮骨架的化合物的制备方法和用途
HK40085586A (en) Pyridazinyl thiazolecarboxamide compound
HK40084227A (zh) 哒嗪基噻唑甲醯胺类化合物
HK40059656A (en) Pyridazinyl thiazolecarboxamide compound
HK40038226B (en) Purine and deazapurine derivatives as pharmaceutical compounds
HK40038226A (en) Purine and deazapurine derivatives as pharmaceutical compounds
HK1257844B (en) Purine and deazapurine derivatives as pharmaceutical compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired